BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32869661)

  • 1. Micropapillary pattern of stage IIIA-N
    Zeng J; Cui X; Cheng L; Chen Y; Du X; Sheng L
    Future Oncol; 2020 Dec; 16(36):3075-3084. PubMed ID: 32869661
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.
    Warth A; Muley T; Meister M; Stenzinger A; Thomas M; Schirmacher P; Schnabel PA; Budczies J; Hoffmann H; Weichert W
    J Clin Oncol; 2012 May; 30(13):1438-46. PubMed ID: 22393100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis.
    Zhao Y; Wang R; Shen X; Pan Y; Cheng C; Li Y; Shen L; Zhang Y; Li H; Zheng D; Ye T; Zheng S; Sun Y; Chen H
    Ann Surg Oncol; 2016 Jun; 23(6):2099-105. PubMed ID: 26842488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
    Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
    Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
    Yamauchi Y; Safi S; Muley T; Warth A; Herth FJF; Dienemann H; Hoffmann H; Eichhorn ME
    Lung Cancer; 2017 Dec; 114():62-67. PubMed ID: 29173768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer.
    Lacoppidan T; Vogelius IR; Pøhl M; Strange M; Persson GF; Nygård L
    Acta Oncol; 2019 Oct; 58(10):1386-1392. PubMed ID: 31271118
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of Lymph Node Micrometastasis and Micropapillary Component and Their Joint Influence on Prognosis of Patients With Stage I Lung Adenocarcinoma.
    Dai C; Xie H; Kadeer X; Su H; Xie D; Ren Y; She Y; Zhu E; Fan Z; Chen T; Qin L; Zheng H; Zhang L; Jiang G; Wu C; Chen C
    Am J Surg Pathol; 2017 Sep; 41(9):1212-1220. PubMed ID: 28692600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma.
    Hung JJ; Jeng WJ; Chou TY; Hsu WH; Wu KJ; Huang BS; Wu YC
    Ann Surg; 2013 Dec; 258(6):1079-86. PubMed ID: 23532112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spread through air spaces is an independent predictor of recurrence in stage III (N2) lung adenocarcinoma.
    Terada Y; Takahashi T; Morita S; Kashiwabara K; Nagayama K; Nitadori JI; Anraku M; Sato M; Shinozaki-Ushiku A; Nakajima J
    Interact Cardiovasc Thorac Surg; 2019 Sep; 29(3):442-448. PubMed ID: 31106332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
    Rajaram R; Correa AM; Xu T; Nguyen QN; Antonoff MB; Rice D; Mehran R; Roth J; Walsh G; Swisher S; Hofstetter WL; Vaporciyan A; Cascone T; Tsao AS; Papadimitrakopoulou VA; Gandhi S; Liao Z; Sepesi B
    Clin Lung Cancer; 2020 Jul; 21(4):e294-e301. PubMed ID: 32089476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma.
    Yeh YC; Kadota K; Nitadori J; Sima CS; Rizk NP; Jones DR; Travis WD; Adusumilli PS
    Eur J Cardiothorac Surg; 2016 Jan; 49(1):e9-e15. PubMed ID: 26377636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy.
    Han H; Zhao Y; Gao Z; Zheng D; Fu F; Zhao Z; Tang Y; Xiang J; Sun Y; Hu H; Chen H
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2115-2122. PubMed ID: 31175463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting occult lymph node metastasis in completely resected lung adenocarcinoma of 3 cm or smaller.
    Hung JJ; Yeh YC; Jeng WJ; Wu YC; Chou TY; Hsu WH
    Eur J Cardiothorac Surg; 2016 Aug; 50(2):329-36. PubMed ID: 26819290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The more the micropapillary pattern in stage I lung adenocarcinoma, the worse the prognosis-a retrospective study on digitalized slides.
    Zombori T; Nyári T; Tiszlavicz L; Pálföldi R; Csada E; Géczi T; Ottlakán A; Pécsy B; Cserni G; Furák J
    Virchows Arch; 2018 Jun; 472(6):949-958. PubMed ID: 29611055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.